OMG!!!!! With respect to the Company’s press
Post# of 145801
![](/assets/46931549/no_avatar_available_thumb.jpg)
With respect to the Company’s press release issued on March 12, 2020, management announces the following correction: Patient #1 had missed one treatment of carboplatin and will continue to be treated with carboplatin and leronlimab. Additional updates about this patient will be included in the next Company update on all cancer patients.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)